Philadelphia Chromosome
Showing 1 - 25 of 949
Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Trial in Tianjin (Vincristine, Daunorubicin, Cyclophosphamide)
Recruiting
- Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- Vincristine
- +9 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Dec 13, 2022
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)
Recruiting
- Acute Lymphoblastic Leukemia
- Philadelphia Chromosome-Positive
- Blinatumomab
- +3 more
-
New York, New York
- +1 more
Nov 10, 2022
Acute Lymphoblastic Leukemia (ALL) Trial (Nilotinib)
No longer available
- Acute Lymphoblastic Leukemia (ALL)
- (no location specified)
Aug 5, 2022
Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)
Recruiting
- Acute Lymphoblastic Leukemia
- Dasatinib
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Nov 28, 2022
Acute,Leukemia, Lymphoid Trial in Tianjin (Dasatinib, prednisone, cyclophosphamide)
Completed
- Acute,Leukemia, Lymphoid
- Dasatinib
- +12 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 2, 2022
Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib)
Not yet recruiting
- Philadelphia-Positive ALL
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Soochow University
Jul 1, 2023
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Frankfurt (Imatinib, Ponatinib, Blinatumomab)
Recruiting
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Imatinib
- +3 more
-
Frankfurt, GermanyDepartment of Medicine, Hematology and Oncology, Goethe Universi
Sep 24, 2023
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)
Recruiting
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Olverembatinib
- +3 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Oct 21, 2022
Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia
- +3 more
- Dasatinib
- Decitabine and Cedazuridine
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Acute Lymphoblastic Leukemia Trial in New York (Ruxolitinib, Dasatinib, Dexamethasone)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- Ruxolitinib
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 25, 2022
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
- Dasatinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 24, 2022
Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,
Recruiting
- Philadelphia Chromosome
- +4 more
- Azacitidine
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jun 23, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +7 more
- Blinatumomab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic
Active, not recruiting
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Dexamethasone
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 2, 2022
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL Trial in Spain (blinatumomab)
Terminated
- Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
-
Badalona, Barcelona, Spain
- +11 more
Jul 26, 2022
Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib combined with chemo)
Not yet recruiting
- Philadelphia-Positive ALL
- Olverembatinib combined with chemotherapy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Jul 17, 2022
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic
Recruiting
- Acute Lymphoblastic Leukemia
- Dasatinib and blinatumomab
-
Bari, Italy
- +16 more
Oct 10, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia Trial
Completed
- Acute Undifferentiated Leukemia
- +13 more
- allopurinol
- +16 more
-
Chicago, IllinoisCancer and Leukemia Group B
Apr 5, 2022
Acute Lymphoblastic Leukemia Trial in Suzhou (cladribine, cytarabine,venetoclax)
Recruiting
- Acute Lymphoblastic Leukemia
- cladribine, cytarabine,venetoclax
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 22, 2022
Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,
Recruiting
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- +4 more
- ADCT-602
-
Monrovia, California
- +1 more
Dec 7, 2022
B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- Biospecimen Collection
- +19 more
- (no location specified)
Nov 8, 2023
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Trial in Worldwide (ABL001, ABL001 +
Active, not recruiting
- Chronic Myelogenous Leukemia
- Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- ABL001
- +3 more
-
Boston, Massachusetts
- +18 more
Jan 19, 2023